Vicore Pharma

Stockholm, November 20, 2025 – Vicore Pharma Holding AB (publ) (STO: VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the DNB Carnegie Nordic Healthcare Conference: 

• Location: Oslo, Norway 
• Format: Presentation and 1×1 meetings 
• Presentation Date and Time: Tuesday, November 25 at 3:35 PM CET 
• Participant: Hans Jeppsson, CFO 

The company’s management team will also be available for meetings at the conference. 

For more information, please contact: 
Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, megan.richards@vicorepharma.com 
Hans Jeppsson, CFO, tel: +46 70 553 14 65, hans.jeppsson@vicorepharma.com 
 
About Vicore Pharma  
Vicore Pharma Holding AB (publ) is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is a first-in-class oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. 
  
The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com